Jehovah's Witness Patients: Interventions for Successful Stem Cell Transplantation Without Blood Product Transfusions for Hematologic Malignancies.

This article presents preventive and supportive measures allowing Jehovah's Witness patients the opportunity to receive a stem cell transplantation without blood product transfusions. METHODS: A literature review was done that included evidence focusing on optimizing hematopoiesis, blood loss prevention, alterations in chemotherapy regimens, and implications for nursing practice. FINDINGS: With proper preventive and supportive care measures, Jehovah's Witness patients can receive stem cell transplantations for hematologic malignancies without blood product transfusions. PMID: 31322623 [PubMed - in process]
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research

Related Links:

This study highlights poor outcomes for patients with BPDCN in the modern era and the need for new treatments. Outcomes from ongoing clinical trials for BPDCN can be evaluated relative to this contemporary cohort.
Source: Blood - Category: Hematology Authors: Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
M, Nagler A Abstract Core binding factor acute myeloid leukemia comprises two subtypes with distinct cytogenetic abnormalities of either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since long-term response to chemotherapy in those leukemias is relatively good, allogeneic hematopoietic stem cell transplantation is considered in patients who relapse and achieve second complete remission. To evaluate the outcomes of allogeneic transplantation in this indication, we studied 631 patients in reported to the European Society for Blood and Marrow Transplantation Registry between the years 2000 and 2014. Leukemi...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
A 48-year-old woman with a history of AIDS and stage IV Hodgkin lymphoma status post chemotherapy and stem cell transplant presented with 8 months of painful perineal erosions and exophytic plaques. Her medical history was significant for acyclovir-resistant herpes simplex virus (HSV) and multiple opportunistic infections. Examination revealed diffuse discontinuous eroded plaques in the perineum, and scattered skin-colored and hyperpigmented exophytic plaques with raised borders and central craters overlying the sacrum, gluteal cleft, and perineum.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
X-linked agammaglobulinemia (XLA), caused by a mutation in the Bruton’s tyrosine kinase (BTK) gene, is rarely reported in patients with recurrent hemophagocytic lymphohistiocytosis (HLH). This mutation leads to significantly reduced numbers of circulatory B cells and serum immunoglobulins in patients. Therefore, they exhibit repetitive bacterial infections since infancy, and immunoglobulin (Ig) replacement therapy is the primary treatment. HLH is a life-threatening condition with manifestations of nonremitting fever, hepatosplenomegaly, cytopenias, coagulopathy, lipid disorder, and multiple organ failure. It is cause...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In conclusion, our data show how oncogenic and tumor-suppressive drivers of cellular senescence act to regulate surveillance processes that can be circumvented to enable SnCs to elude immune recognition but can be reversed by cell surface-targeted interventions to purge the SnCs that persist in vitro and in patients. Since eliminating SnCs can prevent tumor progression, delay the onset of degenerative diseases, and restore fitness; since NKG2D-Ls are not widely expressed in healthy human tissues and NKG2D-L shedding is an evasion mechanism also employed by tumor cells; and since increasing numbers of B cells express NKG2D ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In addition to the mysteries and autobiographies that some of you may be packing for a late summer vacation or long weekend, consider including the current issue of N2. Each article has a plot that will leave you on edge, and here, I will introduce some of them. It is well known that the presentation of MS is diverse, with some patients presenting early with very mild disease and others presenting late with extensive damage from silent disease. Until now, the best biomarker of disease activity and treatment effects has been the MRI. However, MRI has several limitations, including availability, cost, interscan variability, ...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Editor ' s Corner Source Type: research
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation and bone marrow transplants.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans, the compound could help people recover quicker from chemotherapy, radiation and bone marrow transplants.The study, published in Nature Communications,also sheds light on the basic biology behind blood stem cell regeneration and the role of a specific molecular process that is blocked by the new drug. Blood stem cells reside in the bone marrow and produce all of the body ’s blood and immune cells.“We’re very excite...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated safety and efficacy of CD19-specific chimeric antigen receptor (CAR) T cells administered following HDT-ASCT. Eligibility for this study includes poor-risk rel/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive to salvage therapy with: (1) positron emission tomography–positive disease or (2) bone marrow involvement. Patients underwe...
Source: Blood - Category: Hematology Authors: Tags: Immunobiology and Immunotherapy, Transplantation, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
Authors: Nakaya Y, Yoshida M, Tsutsumi M, Fuseya H, Horiuchi M, Yoshimura T, Hayashi Y, Nakao T, Koh KR, Niino D, Inoue T, Yamane T Abstract Hodgkin-like adult T-cell leukemia/lymphoma (ATLL) is a rare variant of ATLL, which represents the early neoplastic phase of ATLL that follows an indolent clinical course compared with typical ATLL. Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disorder characterized by the paralysis of lower limbs and urinary disturbance. Although these diseases are caused by HTLV-1 infection, there are no reports des...
Source: Journal of Clinical and Experimental Hematopathology : JCEH - Category: Hematology Tags: J Clin Exp Hematop Source Type: research
More News: Cancer & Oncology | Chemotherapy | Hematology | Nurses | Nursing | Stem Cell Therapy | Stem Cells | Transplants